A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs AZD 8871 (Primary) ; Umeclidinium/vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 04 Sep 2019 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Planned End Date changed from 23 Sep 2019 to 14 Aug 2019.
- 07 Mar 2019 Planned primary completion date changed from 23 Sep 2019 to 14 Aug 2019.